Investor Presentation First Nine Months of 2022
91
Investor presentation
First nine months of 2022
Novo NordiskⓇ
Large patient overlaps between diabetes, obesity, and CVD have
guided the focused approach in CVD
Population overlap between T2D, obesity and CVD
ASCVD + HF
~425m
people
Focused approach in CVD
Atherosclerosis
Heart failure
Inflammation-driven
pathogenesis
Heart failure
with preserved ejection amyloid cardiomyopathy
fraction
Transthyretin
(ATTR-CM)
IL-6
Type 2 diabetes
~537m
people
Obesity
~764m
people
之仆
CRP
(HFPEF)
> > >
hsCRP as
surrogate endpoint
Improve
outcomes
Amyloid-depletion
through antibody-
mediated
phagocytosis
T2D: Type 2 diabetes, CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; HF: Heart failure; ATTR-CM: Transthyretin Amyloid Cardiomyopathy; LDL-C: Low-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein
Sources: IDF Diabetes Atlas 2021, internal estimate based on European Cardiovascular Disease Statistics, 2017 edition, WHO obesity and overweight fact sheet, 9 June 2021View entire presentation